-Omics and cancer biomarkers: Link to the biological truth or bear the consequences

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 8, 2012, Pages 1229-1235

  Liotta, Lance A ^a   Petricoin III, Emanuel F ^a  

^a GEORGE MASON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

BIOINFORMATICS; BIOLOGY; BODY FLUID; CANCER GROWTH; CANCER RESEARCH; CANCER TISSUE; CARCINOGENESIS; EDITORIAL; ELECTRONIC MEDICAL RECORD; GENE EXPRESSION; HUMAN; MASS SPECTROMETRY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN MICROARRAY;

HUMANS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84864809308     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0635     Document Type: Editorial

References (39)

1. Poste G. Bring on the biomarkers. Nature 2011;469:156-7.
2. Service RF. Proteomics ponders prime time. Science 2008;321:1758-61.
3. The Cancer Genome Atlas. Available from: http://cancergenome.nih.gov [accessed June 27, 2012].
4. Vermaat JS, Nijman IJ, Koudijs MJ, Gerritse FL, Scherer SJ, Mokry M, et al. Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. Clin Cancer Res 2012;18:688-99.
5. Belluco C, Mammano E, Petricoin E, Prevedello L, Calvert V, Liotta L, et al. Kinase substrate protein microarray analysis of human colon cancer and hepatic metastasis. Clin Chim Acta 2005;357:180-3. (Pubitemid 40884598)
6. Holzer TR, Fulford AD, Arkins AM, Grondin JM, Mundy CW, Nasir A, et al. Ischemic time impacts biological integrity of phospho-proteins in PI3K/Akt, Erk/MAPK, and p38 MAPK signaling networks. Anticancer Res 2011;31:2073-81.
7. Espina V, Mueller C. Reduction of preanalytical variability in specimen procurement for molecular profiling. Methods Mol Biol 2012;823:49-57.
8. Espina V, Edmiston KH, Heiby M, Pierobon M, Sciro M, Merritt B, et al. A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics 2008;7:1998-2018.
9. Hicks DG, Boyce BF. The challenge and importance of standardizing pre-analytical variables in surgical pathology specimens for clinical care and translational research. Biotech Histochem 2012;87:14-7.
10. Mueller C, Edmiston KH, Carpenter C, Gaffney E, Ryan C, Ward R, et al. One-step preservation of phosphoproteins and tissue morphology at room temperature for diagnostic and research specimens. PLoS One 2011;6:e23780.
11. Espina V, Mueller C, Edmiston K, Sciro M, Petricoin EF, Liotta LA. Tissue is alive: new technologies are needed to address the problems of protein biomarker pre-analytical variability. Proteomics Clin Appl 2009;3:874-882.
12. Rountree CB, Van Kirk CA, You H, Ding W, Dang H, VanGuilder HD, et al. Clinical application for the preservation of phospho-proteins through in situ tissue stabilization. Proteome Sci 2010;8:61.
13. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
14. Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, et al. Laser capture microdissection (LCM). Science 1996;274:998-1001.
15. Jacobsen M, Repsilber D, Gutschmidt A, Neher A, Feldmann K, Mollenkopf HJ, et al. Deconfounding microarray analysis - independent measurements of cell type proportions used in a regression model to resolve tissue heterogeneity bias. Methods Inf Med 2006;45:557-6.
16. Shang B, Zhang G, Pan Y, Zhou Q. Deciphering the key features of malignant tumor microenvironment for anti-cancer therapy. Cancer Microenviron. 2012 May 17. [Epub ahead of print].
17. Hawthorn L, Stein L, Panzarella J, Loewen GM, Baumann H. Characterization of cell-type specific profiles in tissues and isolated cells from squamous cell carcinomas of the lung. Lung Cancer 2006;53:129-42. (Pubitemid 43994230)
18. Henare K, Wang L, Wang LC, Thomsen L, Tijono S, Chen CJ, et al. Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA. Br J Cancer 2012;106:1134-47.
19. Khamis ZI, Sahab ZJ, Sang QX. Active roles of tumor stroma in breast cancer metastasis. Int J Breast Cancer 2012;2012:57402.
20. Silvestri A, Colombatti A, Calvert VS, Deng J, Mammano E, Belluco C, et al. Protein pathway biomarker analysis of human cancer reveals requirement for upfront cellular-enrichment processing. Lab Invest 2010;90:787-96.
21. Wulfkuhle JD, Speer R, Pierobon M, Laird J, Espina V, Deng J, et al. Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res 2008;7:1508-17.
22. Bonner RF, Emmert-Buck M, Cole K, Pohida T, Chuaqui R, Goldstein S, et al. Laser capture microdissection: molecular analysis of tissue. Science 1997;278:1481-3.
23. Espina V, Wulfkuhle JD, Calvert VS, VanMeter A, Zhou W, Coukos G, et al. Laser-capture microdissection. Nat Protoc 2006;1:586-603.
24. Issaq HJ, Fox SD, Chan KC, Veenstra TD. Global proteomics and metabolomics in cancer biomarker discovery. J Sep Sci 2011;34:3484-92.
25. Ebhardt HA, Sabidó E, Hüttenhain R, Collins B, Aebersold R. Range of protein detection by selected/multiple reaction monitoring mass spectrometry in an unfractionated human cell culture lysate. Proteomics 2012;12:1185-93.
26. Brown PO, Palmer C. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med 2009;6:e1000114.
27. Domanski D, Percy AJ, Yang J, Chambers AG, Hill JS, Freue GV, et al. MRM-based multiplexed quantitation of 67 putative cardiovascular disease biomarkers in human plasma. Proteomics 2012;12:1222-43.
28. Huang PH, Miraldi ER, Xu AM, Kundukulam VA, Del Rosario AM, Flynn RA, et al. Phosphotyrosine signaling analysis of site-specific mutations on EGFRvIII identifies determinants governing glioblastoma cell growth. Mol Biosyst 2010;6:1227-37.
29. Paweletz CP, Charboneau L, Roth MJ, Bichsel VE, Simone NL, Chen T, et al. Reverse phase proteomic microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2006;20:1981-9. (Pubitemid 32458030)
30. Rapkiewicz A, Espina V, Zujewski JA, Lebowitz PF, Filie A, Wulfkuhle J, et al. The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology. Cancer 2007;111:173-84. (Pubitemid 46982695)
31. Ibarra-Drendall C, Troch MM, Barry WT, Broadwater G, Petricoin EF III, Wulfkuhle J, et al. Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways. Breast Cancer Res Treat 2012;132:487-98.
32. Ahmad S, Sundaramoorthy E, Arora R, Sen S, Karthikeyan G, Sengupta S. Progressive degradation of serum samples limits proteomic biomarker discovery. Anal Biochem 2009;394:237-42.
33. Guerrier L, Fortis F, Boschetti E. Solid-phase fractionation strategies applied to proteomics investigations. Methods Mol Biol 2012;818:11-33.
34. Petricoin EF, Belluco C, Araujo RP, Liotta LA. The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer 2006;6:961-7. (Pubitemid 44862680)
35. Kulasingam V, Smith CR, Batruch I, Diamandis EP. Immuno-mass spectrometry: quantification of low-abundance proteins in biological fluids. Methods Mol Biol 2011;728:207-18.
36. Luchini A, Geho DH, Bishop B, Tran D, Xia C, Dufour RL, et al. Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation. Nano Lett 2008;8:350-61. (Pubitemid 351177827)
37. Tamburro D, Fredolini C, Espina V, Douglas TA, Ranganathan A, Ilag L, et al. Multifunctional core-shell nanoparticles: discovery of previously invisible biomarkers. J Am Chem Soc 2011;133:19178-88.
38. Taguchi A, Politi K, Pitteri SJ, Lockwood WW, Faça VM, Kelly-Spratt K, et al. Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell 2011;20:289-99.
39. Harsha HC, Pandey A. Phosphoproteomics in cancer. Mol Oncol 2010;4:482-95.